Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1

被引：0
|
作者：
Javier Sánchez
Valeria Nicolini
Linda Fahrni
Inja Waldhauer
Antje‑Christine Walz
Candice Jamois
Stephen Fowler
Silke Simon
Christian Klein
Pablo Umaña
Lena E. Friberg
Nicolas Frances
机构：
[1] Roche Innovation Center Basel,Roche Pharma Research and Early Development
[2] F. Hoffmann-La Roche Ltd.,Department of Pharmacy
[3] Uppsala University,Roche Pharma Research and Early Development
[4] Roche Innovation Center Zurich,undefined
来源：
The AAPS Journal | / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 22 条
  • [1] Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1
    Sanchez, Javier
    Nicolini, Valeria
    Fahrni, Linda
    Waldhauer, Inja
    Walz, Antje-Christine
    Jamois, Candice
    Fowler, Stephen
    Simon, Silke
    Klein, Christian
    Umana, Pablo
    Friberg, Lena
    Frances, Nicolas
    AAPS JOURNAL, 2022, 24 (06):
  • [2] Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1
    Javier Sánchez
    Valeria Nicolini
    Linda Fahrni
    Inja Waldhauer
    Antje-Christine Walz
    Candice Jamois
    Stephen Fowler
    Silke Simon
    Christian Klein
    Pablo Umaña
    Lena E. Friberg
    Nicolas Frances
    The AAPS Journal, 24
  • [3] Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1 (vol 24, 106, 2022)
    Sanchez, Javier
    Nicolini, Valeria
    Fahrni, Linda
    Waldhauer, Inja
    Antje-Christine, Walz
    Jamois, Candice
    Fowler, Stephen
    Simon, Silke
    Klein, Christian
    Umana, Pablo
    Friberg, Lena E.
    Frances, Nicolas
    AAPS JOURNAL, 2023, 25 (03):
  • [4] Preclinical Characterization of Combinability and Potential Synergy of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody with Chemotherapy and PD-1/PD-L1 Blockade
    Sun, Liping Laura
    Wang, Peiyin
    Clark, Robyn
    Hristopoulos, Maria
    Ellerman, Diego
    Mathieu, Mary
    Chu, Yu-Waye
    Wang, Hong
    Totpal, Klara
    Ebens, Allen J.
    Polson, Andrew G.
    Gould, Stephen
    BLOOD, 2016, 128 (22)
  • [5] Microenvironment-responsive anti-PD-L1 x CD3 bispecific T-cell engager for solid tumor immunotherapy
    Liu, Dingkang
    Bao, Lichen
    Zhu, Haichao
    Yue, Yali
    Tian, Jing
    Gao, Xiangdong
    Yin, Jun
    JOURNAL OF CONTROLLED RELEASE, 2023, 354 : 606 - 614
  • [6] Systems Pharmacology Modeling to Support Clinical Development of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody
    Hosseini, Iraj
    Gadkar, Kapil
    Stefanich, Eric
    Li, Chi-Chung
    Sun, Laura
    Chu, Yu-Waye
    Ramanujan, Saroja
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S57 - S57
  • [7] Systems pharmacology modeling of anti-CD20/CD3 T-cell dependent bispecific antibody and its application to clinical trial design
    Hosseini, Iraj
    Gadkar, Kapil
    Stefanich, Eric
    Li, Chi-Chung
    Sun, Laura
    Chu, Yu-Waye
    Ramanujan, Saroja
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [8] Pharmacodynamic response to HER2/CD3 bispecific antibody (HER2-TDB): evidence of T-cell recruitment and further rationale for combination treatment with anti-PD-L1
    Li, Ji
    Hristopoulos, Maria
    Clark, Robyn
    Johnston, Jennifer
    Slaga, Dion
    Wang, Bu-Er
    Cubas, Rafael
    Totpal, Klara
    Junttila, Melissa R.
    Junttila, Teemu T.
    CANCER RESEARCH, 2016, 76
  • [9] A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies
    Moore, Gregory L.
    Zeng, Veronica G.
    Diaz, Juan E.
    Bonzon, Christine
    Avery, Kendra N.
    Rashid, Rumana
    Qi, Jing
    Nam, Dong Hyun
    Jacinto, Jonathan
    Dragovich, Matthew A.
    Kim, Yoon Kyung
    Balcazar, Karen P.
    Bakhit, Charles G.
    Eivazi, Araz
    Nguyen, Hanh
    Muchhal, Umesh S.
    Szymkowski, David E.
    Desjarlais, John R.
    Hedvat, Michael
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (03) : 331 - 344
  • [10] A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer models
    Okpalanwaka, Izuchukwu F.
    Daugherity, Elizabeth A.
    McCormick, Amanda L.
    Anderson, Trevor S.
    Smith, Savanna L.
    Lawrence, Caryn
    Lowe, Devin B.
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
123